Related Experiment Video

Updated: Sep 21, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Global best practices consensus: Long-term management of patients with hybrid centrifugal flow left ventricular

Christopher Hayward1, Iki Adachi2, Sylvie Baudart3

  • 1Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia.

The Journal of Thoracic and Cardiovascular Surgery
|May 27, 2022
PubMed

Insights

This guideline offers best practices for managing patients with the HeartWare HVAD System, addressing the declining global expertise. It highlights key differences compared to the HeartMate 3 ventricular assist device.

Area of Science:

  • Cardiology
  • Medical Devices
  • Mechanical Circulatory Support

Background:

  • The HeartWare HVAD System (HVAD) remains implanted in approximately 4000 patients post-withdrawal from sale.
  • Diminishing global experience necessitates updated management strategies for ongoing HVAD support.

Purpose of the Study:

  • To provide a global consensus document summarizing key management recommendations for patients with ongoing HVAD support.
  • To highlight differences in management compared to the HeartMate 3 ventricular assist device.

Main Methods:

  • International experts in HVAD management convened to summarize patient and pump management.
  • Clinicians from high-implant HVAD centers reviewed literature and shared experiences to form a consensus.
  • Key differences in managing patients with the HeartMate 3 were identified.

Main Results:

  • A guideline document with specific protocols and techniques for ongoing HVAD patient management was developed.
  • Best practice techniques from international centers are summarized.
  • Differences in approach to HeartMate 3 management are highlighted.

Conclusions:

  • This consensus guideline addresses the decreasing worldwide experience in HVAD patient management.
  • It offers a summary of best practices from international centers for ongoing HVAD support.
  • Key differences in HeartMate 3 management are emphasized.
Abstract

Keywords:
HeartWare HVADadverse eventsanticoagulationblood pressureleft ventricular assist devicemanagement guidelines

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
42
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
44
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
31
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
56
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
36